Open-house rebate agreement for epinephrine prefilled syringe/prefilled pen
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Epinephrin (ATC-Code nach WHO: C01CA24) in der Darr. Fertigspritze/Fertigpen
Opportunity Score
Why this score?
Opportunity
46 / 100
Complexity
58 / 100
Risk factors
Participation documents must be submitted via the DTVP communication function, but the notice says some portal instruct...
Only pharmaceutical companies within the meaning of § 4(18) AMG may participate for the offered medicinal products, and...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Sep 2026
- Non-exclusive rebate agreements for epinephrine medicinal products in prefilled syringe/prefilled pen form, excluding 500 micrograms.
- Open-House participation model with contracts available to all interested eligible pharmaceutical companies during the participation period.
Show full summary
This is an Open-House supply arrangement for non-exclusive pharmaceutical rebate agreements under §130a(8) SGB V for epinephrine (ATC C01CA24) in prefilled syringe/prefilled pen form, excluding 500 micrograms. The lead buyer is AOK PLUS. Participation is open to all eligible pharmaceutical companies during the participation period, with no individual negotiations and no supply exclusivity. Submission is electronic via DTVP communication functions, but the notice says some portal instructions are technically misleading and the participation documents must be obtained from the project room. No contract value is stated.
Risks
Participation documents must be submitted via the DTVP communication function, but the notice says some portal instruct...
Only pharmaceutical companies within the meaning of § 4(18) AMG may participate for the offered medicinal products, and...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal products.
- The company must accept the participation requirements and the rebate agreement terms.
Administrative
- An application for access to the project room is required before downloading the participation documents.
Buyer
Location
Erfurt, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Open-house rebate agreement for epinephrine prefilled syringe/prefilled pen
Single lot covering non-exclusive rebate agreements for medicinal products with epinephrine (ATC C01CA24) in prefilled syringe/prefilled pen presentation, excluding 500 micrograms. The arrangement is an Open-House model with no exclusivity and no individual negotiations. Place of performance is Dresden, Germany, with performance geography stated as Germany, Saxony and Thuringia in the notice text.
Location
Duration
Category
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Epinephrin (ATC-Code nach WHO: C01CA24) in der Darr. Fertigspritze/Fertigpen
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 31 Jul 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 504736-2025
Documents (1)
Similar tenders
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Belgium – Pharmaceutical products – Antimycotica
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Opportunity Score
Why this score?
Opportunity
46 / 100
Complexity
58 / 100
Risk factors
Participation documents must be submitted via the DTVP communication function, but the notice says some portal instruct...
Only pharmaceutical companies within the meaning of § 4(18) AMG may participate for the offered medicinal products, and...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications